ras p21 immunohistochemical detection in human endometrial carcinomas

Gynecol Obstet Invest. 1997;44(2):132-5. doi: 10.1159/000291504.

Abstract

Tissue samples of 40 patients with histologically confirmed endometrial cancer were analyzed immunohistochemically on paraffin-embedded specimens to detect ras p21 protein expression. The relationship between p21 protein expression and clinicopathological findings was also analyzed. The intensity and distribution of specific cytoplasmatic staining were evaluated semiquantitatively by counting the immunohistochemical H-score. ras p21 expression was found in 30 (75%) of 40 human endometrial carcinomas, regardless of the clinical stage of the disease. Positive immunostaining for p21 was noted in 68% of stage I-II and in all 8 of the advanced stages (III-IV according to FIGO) of endometrial carcinomas. Myometrial invasion was related to ras p21 immunostaining (p = 0.009), however, no correlation between histological findings and ras p21 expression was observed.

Publication types

  • Comparative Study

MeSH terms

  • Adenocarcinoma / chemistry*
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Adenocarcinoma, Clear Cell / chemistry*
  • Adenocarcinoma, Clear Cell / metabolism
  • Adenocarcinoma, Clear Cell / pathology
  • Aged
  • Aged, 80 and over
  • Animals
  • Antibodies, Monoclonal / immunology
  • Carcinoma, Adenosquamous / chemistry*
  • Carcinoma, Adenosquamous / metabolism
  • Carcinoma, Adenosquamous / pathology
  • Cohort Studies
  • Endometrial Neoplasms / chemistry*
  • Endometrial Neoplasms / metabolism
  • Endometrial Neoplasms / pathology
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Neoplasm Staging
  • Oncogene Protein p21(ras) / analysis*
  • Oncogene Protein p21(ras) / biosynthesis
  • Oncogene Protein p21(ras) / genetics
  • Rabbits

Substances

  • Antibodies, Monoclonal
  • Oncogene Protein p21(ras)